Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|June 22, 2018

A New Solution to Significantly Enhance the Clinical Trial Experience for Patients, Families, and Carers

Milton Keynes and London, UK, 22 June 2018/ - - Leading clinical trials specialists, Medical Research Network (MRN) and mdgroup, announced today a global strategic partnership to deliver an integrated, global solution to address specific challenges related to patient study visits.  By delivering clinical trial visits at home or in the clinic, this new partnership will enhance clinical trial experiences for patients, families and carers and help sponsors complete clinical trials on time and within budget.   The pharmaceutical and biotech industries face significant challenges reducing the time-to-market of new products. Timely completion of clinical trials is a crucial scientific and commercial target to maximise the period of patent protection; however, recruitment and retention rates in clinical trials are often negatively impacted by the burden, perceived or real, of clinical trial participation.   New data collected by mdgroup suggests choice of study visit location plays a significant role in patients’ likelihood of clinical trial enrolment and participation, with 1-in-2 dropouts attributed to travel and logistic issues. The MRN-mdgroup partnership combines global clinical trial and travel expertise to deliver study visits at home or in the clinic to significantly reduce the burden of clinical trial participation for patients, families and carers.   MRN CEO, Graham Wylie believes this new integrated approach is exactly what’s needed, “patient centric services work better in combination, producing a synergistic added value for the patient across all visits, not just a few, enhancing the improved recruitment and retention from each service alone”.   Echoing these sentiments, mdgroup CEO, Tarquin Scadding-Hunt believes a patient-centric approach is central to the future success of studies, “by delivering optimal patient choice of study visit location – at home or in the clinic – we enhance clinical trial experiences for patients, families and carers to reduce the burden of participation”.   Through this partnership, sponsors and CROs access the combined, global expertise of MRN and mdgroup, including clinical trial professionals, travel and logistics executives and community nurses to deliver study visits – at home or in clinic – across diverse cultures and geographies, with the experience to address specific challenges relating to different diseases and patient populations.     About Medical Research Network   Established in 2006, MRN is the world's leading international provider of both Home Trial Support (HTS) and Site Nurse Support (SNS) solutions for patients in clinical trials. Operating in over 40 countries and with offices in Chicago USA, Milton Keynes UK and Madrid Spain, MRN have now completed over 35,000 home visits and supported hundreds of sites within trials, driving a CAGR of 40% per annum since inception 12 years ago. www.themrn.co.uk | LinkedIn | Twitter   About mdgroup  mdgroup is committed to getting life-saving products to patients faster, by providing services and software solutions that help pharmaceutical and biotech companies engage employees, physicians and patients in clinical trials and drug development. mdgroup is the parent company of mdevents, patientprimary and mdtravel. www.mdgroup.com | LinkedIn | Facebook | Twitter


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.